JP2018502120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502120A5 JP2018502120A5 JP2017535690A JP2017535690A JP2018502120A5 JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5 JP 2017535690 A JP2017535690 A JP 2017535690A JP 2017535690 A JP2017535690 A JP 2017535690A JP 2018502120 A5 JP2018502120 A5 JP 2018502120A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- cpi
- antigen
- binding fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 88
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 74
- 102000036639 antigens Human genes 0.000 claims description 74
- 108091007433 antigens Proteins 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 66
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 26
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 26
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 26
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 26
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 26
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 26
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 26
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 210000003679 cervix uteri Anatomy 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 210000003238 esophagus Anatomy 0.000 claims description 6
- 210000003128 head Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 210000003739 neck Anatomy 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 210000000664 rectum Anatomy 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 210000001685 thyroid gland Anatomy 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 238000011269 treatment regimen Methods 0.000 claims description 6
- 210000003932 urinary bladder Anatomy 0.000 claims description 6
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000013256 coordination polymer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 238000011282 treatment Methods 0.000 description 3
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098568P | 2014-12-31 | 2014-12-31 | |
| US62/098,568 | 2014-12-31 | ||
| US201562106526P | 2015-01-22 | 2015-01-22 | |
| US62/106,526 | 2015-01-22 | ||
| US201562118165P | 2015-02-19 | 2015-02-19 | |
| US62/118,165 | 2015-02-19 | ||
| PCT/US2015/067269 WO2016109310A1 (en) | 2014-12-31 | 2015-12-22 | Combination tumor immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187016A Division JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502120A JP2018502120A (ja) | 2018-01-25 |
| JP2018502120A5 true JP2018502120A5 (OSRAM) | 2019-02-14 |
| JP6885867B2 JP6885867B2 (ja) | 2021-06-16 |
Family
ID=56284932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535690A Active JP6885867B2 (ja) | 2014-12-31 | 2015-12-22 | 組合せ腫瘍免疫療法 |
| JP2020187016A Withdrawn JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187016A Withdrawn JP2021014465A (ja) | 2014-12-31 | 2020-11-10 | 組合せ腫瘍免疫療法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10682365B2 (OSRAM) |
| EP (2) | EP3835312A1 (OSRAM) |
| JP (2) | JP6885867B2 (OSRAM) |
| CN (2) | CN107428813B (OSRAM) |
| AU (2) | AU2015374385B2 (OSRAM) |
| CY (1) | CY1123868T1 (OSRAM) |
| DK (1) | DK3240801T3 (OSRAM) |
| ES (1) | ES2856844T3 (OSRAM) |
| HR (1) | HRP20210200T1 (OSRAM) |
| HU (1) | HUE053145T2 (OSRAM) |
| LT (1) | LT3240801T (OSRAM) |
| MX (2) | MX393750B (OSRAM) |
| NZ (2) | NZ734144A (OSRAM) |
| PL (1) | PL3240801T3 (OSRAM) |
| PT (1) | PT3240801T (OSRAM) |
| RS (1) | RS61470B1 (OSRAM) |
| SI (1) | SI3240801T1 (OSRAM) |
| SM (1) | SMT202100094T1 (OSRAM) |
| WO (1) | WO2016109310A1 (OSRAM) |
| ZA (1) | ZA202005298B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200030375A1 (en) * | 2012-06-27 | 2020-01-30 | Kenichiro Hasumi | Therapy and methods of introducing immature dendritic cells and/or cytoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors |
| PT2992017T (pt) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| EP3835312A1 (en) * | 2014-12-31 | 2021-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
| WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| BR112017025562A2 (pt) * | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| EP3682889B1 (en) * | 2015-08-06 | 2023-02-01 | Regents of the University of Minnesota | Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| EP3213768A1 (en) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
| WO2017173334A1 (en) * | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| EP3558360A1 (en) * | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| EP3603668A4 (en) * | 2017-03-29 | 2021-01-06 | Terumo Kabushiki Kaisha | ADDITIVE COMPOSITION, VACCINE COMPOSITION AND MEDICINAL KIT WITH IT |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3752194A4 (en) * | 2018-02-13 | 2022-03-16 | Checkmate Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY |
| IL277680B2 (en) | 2018-04-09 | 2025-08-01 | Checkmate Pharmaceuticals Inc | Packaging oligonucleotides into virus-like particles |
| WO2019200238A1 (en) | 2018-04-14 | 2019-10-17 | Dynavax Technologies Corporation | Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer |
| CN108486120B (zh) * | 2018-04-28 | 2019-12-06 | 新乡医学院 | 一种新型CpG ODN序列及其在抗黑色素瘤上的应用 |
| EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| CN115991787A (zh) | 2018-06-05 | 2023-04-21 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| WO2020081398A1 (en) * | 2018-10-14 | 2020-04-23 | Dynavax Technologies Corporation | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer |
| WO2020081986A1 (en) * | 2018-10-18 | 2020-04-23 | Idera Pharmaceuticals, Inc. | Tlr9 modulators for treating cancer |
| WO2020123388A1 (en) | 2018-12-11 | 2020-06-18 | Board Of Regents, The University Of Texas System | Radiotherapies and uses thereof |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| US11613755B2 (en) | 2019-12-31 | 2023-03-28 | Industrial Technology Research Institute | Nucleic acid-drug complex and use thereof |
| WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
| CN114099535B (zh) * | 2020-12-10 | 2023-01-03 | 南京吉迈生物技术有限公司 | Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物 |
| JP2024512765A (ja) * | 2021-04-01 | 2024-03-19 | トリサルース・ライフ・サイエンシズ・インコーポレイテッド | トール様受容体アゴニストを使用したがん治療 |
| US11898147B2 (en) * | 2021-09-06 | 2024-02-13 | National Health Research Institutes | CpG-oligodeoxynucleotide compounds in combination with immune modulators for cancer immunotherapy |
| US20250009918A1 (en) * | 2021-11-24 | 2025-01-09 | Wisconsin Alumni Research Foundation | Nanoparticles for potentiating effects of radiation therapy on anti-cancer immunotherapy |
| JP2025501311A (ja) | 2022-01-03 | 2025-01-17 | チェックメイト ファーマシューティカルズ， インコーポレイテッド | 自然免疫活性化因子に応答するための転写バイオマーカー |
| CN114982711B (zh) * | 2022-05-30 | 2023-11-10 | 广东省人民医院 | 小鼠胃间质瘤自发成瘤模型及其构建方法和应用 |
| WO2025117535A1 (en) * | 2023-11-29 | 2025-06-05 | Zola Therapeutics Inc. | Synthetic immunostimulatory nucleic acids for immunotherapy of cancer and other diseases |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| ATE75483T1 (de) | 1981-10-23 | 1992-05-15 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100238712B1 (ko) | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
| US5859231A (en) | 1993-09-03 | 1999-01-12 | Duke University | Synthesis of oligonucleotides with boranophosphonate linkages |
| US5658738A (en) | 1994-05-31 | 1997-08-19 | Becton Dickinson And Company | Bi-directional oligonucleotides that bind thrombin |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US20020088014A1 (en) | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| DE19826758C1 (de) | 1998-06-15 | 1999-10-21 | Soft Gene Gmbh | Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte |
| JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法 |
| ES2283139T5 (es) | 1998-10-23 | 2018-03-05 | Amgen Inc. | Métodos y composiciones para la prevención y tratamiento de la anemia |
| ATE397457T1 (de) | 1998-12-03 | 2008-06-15 | Univ California | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen |
| SI2112166T1 (sl) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| ES2306711T3 (es) | 2000-04-21 | 2008-11-16 | Amgen Inc. | Metodo y composicion destinada a la prevencion y al tratamiento de la anemia. |
| PT1391464E (pt) | 2001-04-27 | 2007-11-15 | Kirin Pharma Kk | Anticorpo monoclonal anti-cd40 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| NZ552377A (en) | 2001-08-17 | 2008-08-29 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
| CA2492826C (en) | 2001-09-14 | 2016-12-13 | Cytos Biotechnology Ag | Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use |
| US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| ZA200507562B (en) | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
| EP1699480B1 (de) | 2003-12-30 | 2011-06-15 | Mologen AG | Allogenes tumortherapeutikum |
| CN1918293A (zh) | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子 |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101268101A (zh) | 2005-07-07 | 2008-09-17 | 科利制药集团公司 | 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗 |
| JP2009515896A (ja) * | 2005-11-11 | 2009-04-16 | ファイザー・インク | 免疫調節性オリゴデオキシヌクレオチドを使用する併用療法 |
| NZ569741A (en) | 2005-12-14 | 2012-02-24 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| PT1991678E (pt) | 2006-02-15 | 2015-11-25 | Adiutide Pharmaceuticals Gmbh | Composições e métodos para formulações de oligonucleótidos |
| US7993648B2 (en) * | 2006-05-03 | 2011-08-09 | The Regents of the Universitry of Colorado | Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| JP5437797B2 (ja) | 2006-06-12 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法 |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| CA2671873C (en) | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides containing high concentrations of guanine monomers |
| WO2009022215A1 (en) | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| SG11201406592QA (en) * | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
| US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
| EP3835312A1 (en) * | 2014-12-31 | 2021-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
| BR112017025562A2 (pt) * | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
| US9917100B2 (en) | 2015-11-20 | 2018-03-13 | Sandisk Technologies Llc | Three-dimensional NAND device containing support pedestal structures for a buried source line and method of making the same |
| ITUA20162720A1 (it) | 2016-04-19 | 2017-10-19 | Risco Spa | Apparecchiatura per preparare un prodotto alimentare |
-
2015
- 2015-12-22 EP EP21151085.4A patent/EP3835312A1/en active Pending
- 2015-12-22 CN CN201580075681.0A patent/CN107428813B/zh active Active
- 2015-12-22 LT LTEP15876030.6T patent/LT3240801T/lt unknown
- 2015-12-22 WO PCT/US2015/067269 patent/WO2016109310A1/en not_active Ceased
- 2015-12-22 US US15/540,913 patent/US10682365B2/en active Active
- 2015-12-22 SM SM20210094T patent/SMT202100094T1/it unknown
- 2015-12-22 ES ES15876030T patent/ES2856844T3/es active Active
- 2015-12-22 SI SI201531505T patent/SI3240801T1/sl unknown
- 2015-12-22 NZ NZ734144A patent/NZ734144A/en unknown
- 2015-12-22 HR HRP20210200TT patent/HRP20210200T1/hr unknown
- 2015-12-22 EP EP15876030.6A patent/EP3240801B1/en active Active
- 2015-12-22 CN CN202110797632.5A patent/CN113813386A/zh active Pending
- 2015-12-22 RS RS20210195A patent/RS61470B1/sr unknown
- 2015-12-22 NZ NZ771297A patent/NZ771297A/en unknown
- 2015-12-22 HU HUE15876030A patent/HUE053145T2/hu unknown
- 2015-12-22 DK DK15876030.6T patent/DK3240801T3/da active
- 2015-12-22 MX MX2017008658A patent/MX393750B/es unknown
- 2015-12-22 PT PT158760306T patent/PT3240801T/pt unknown
- 2015-12-22 JP JP2017535690A patent/JP6885867B2/ja active Active
- 2015-12-22 AU AU2015374385A patent/AU2015374385B2/en active Active
- 2015-12-22 PL PL15876030T patent/PL3240801T3/pl unknown
-
2017
- 2017-06-28 MX MX2022008338A patent/MX2022008338A/es unknown
-
2020
- 2020-05-05 US US16/867,296 patent/US20200281953A1/en active Pending
- 2020-08-20 ZA ZA2020/05298A patent/ZA202005298B/en unknown
- 2020-08-26 AU AU2020223671A patent/AU2020223671C1/en active Active
- 2020-11-10 JP JP2020187016A patent/JP2021014465A/ja not_active Withdrawn
-
2021
- 2021-02-16 CY CY20211100130T patent/CY1123868T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502120A5 (OSRAM) | ||
| HRP20210200T1 (hr) | Kombinirana antitumorska imunoterapija | |
| Abbott et al. | Cancer and the immune system: the history and background of immunotherapy | |
| Hu et al. | The abscopal effect of radiation therapy: what is it and how can we use it in breast cancer? | |
| JP2016536286A5 (OSRAM) | ||
| Borg et al. | Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study | |
| JP2015532292A5 (OSRAM) | ||
| JP2015534577A5 (OSRAM) | ||
| JP2019532047A5 (OSRAM) | ||
| RU2017117664A (ru) | Комбинация | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2017533912A5 (OSRAM) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX385338B (es) | Combinación de vacunación e inhibición de la trayectoria pd-1. | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2016540042A5 (OSRAM) | ||
| JP2019504105A5 (OSRAM) | ||
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| JP2016502515A5 (OSRAM) | ||
| JP2011103891A5 (OSRAM) | ||
| JP2017538680A5 (OSRAM) | ||
| Feng et al. | Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma | |
| Fleischmann et al. | Radioimmunotherapy: future prospects from the perspective of brachytherapy | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| JP2018509423A5 (OSRAM) |